Joint Programming Initiative on Antimicrobial Resistance
 

Projects awarded funding within the 6th JPIAMR Joint Call

Ten projects have been awarded funding within the JPIAMR 6th transnational call: “Innovations against antibiotic-resistant bacteria: New targets, compounds and tools”. The total funding amount is 12,8 M€.

The call was launched in January 2018 and supported by 16 research-funding organisations from JPIAMR member countries. The primary aim of the call is to combine the resources, infrastructures, and research strengths of multiple countries in order to address the identification and validation of new targets, the development of new therapies, and new tools for new treatments (including new antibiotics).

104 applications were received, involving 468 partners. The evaluation process included international experts that performed remote evaluation and constituted the peer review panel. In total ten transnational projects were granted funding.

For any questions concerning the call results, please contact the Joint Call Secretariat:

Agence Nationale de la Recherche
Phone: +33 (0)1 78 09 80 44
Email: JPI-AMRCalls@agencerecherche.fr

The projects awarded funding within the call are:

AcronymProject titleCoordinatorAffiliationCountries
ANTIBIO-LABAnti-Biofilm therapies using Local Application of bacteriophagesFintan MoriartyAO Research Institute DavosBelgium, Switzerland, Germany
Anti-PersistenceFighting antibiotic-resistant superbugs with anti-persister compounds targeting the stringent responseAbel Garcia-PinoUniversité Libre de BruxellesBelgium, France, Spain, Poland
CRISPRattacKAdvancing CRISPR antimicrobials to combat the bacterial pathogen Klebsiella pneumoniaeChase BeiselHelmholtz Center for Infection ResearchIsraël, France, Germany
DISRUPTFighting antimicrobial resistant infections by high-throughput discovery of biofilm-disrupting agents and mechanismsMorten KjosNorwegian University of Life SciencesNorway, Germany, Switzerland
ExploreExploration of the TPP riboswitch as a new target for antibioticsRuth BrenkUniversity of BergenCanada, Czech Republic, Latvia, Germany, Norway
FLAV4AMRFlavodoxin inhibitors to kill resistant bacteriaJavier SanchoUniversity of ZaragozaFrance, Germany, Spain
MTI4MDR-TBDevelopment of novel Mycobacterial Tolerance Inhibitors (MTIs) against MDR/XDR tuberculosisFredrik AlmqvistUmeå UniversityFrance, Norway, Spain, Sweden, USA
RESET-MERestoring E. coli Sensitivity for Antibiotics by blocking TolC-Mediated EffluxBjörn WindshügelFraunhofer Institute for Molecular Biology and Applied Ecology IMEFinland, Germany, Italy, Latvia,
RIBOTARGETDevelopment of Novel Ribosome-targeting AntibioticsDaniel WilsonUniversity of HamburgGermany, Czech Republic, France, Sweden, Switzerland, Italy
SCANDesign, Synthesis and Lead Generation of Novel Siderophore Conjugates for the Detection and Treatment of Infections by Gram-Negative PathogensMark BrönstrupHelmholtz Centre for Infection ResearchFrance, Germany, Israël